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Perspectives on ENCODE
The ENCODE Project Consortium*, Michael P. Snyder1,2 ✉, Thomas R. Gingeras3,  
Jill E. Moore4, Zhiping Weng4,5,6, Mark B. Gerstein7, Bing Ren8,9, Ross C. Hardison10,  
John A. Stamatoyannopoulos11,12,13, Brenton R. Graveley14, Elise A. Feingold15,  
Michael J. Pazin15, Michael Pagan15, Daniel A. Gilchrist15, Benjamin C. Hitz1, J. Michael Cherry1, 
Bradley E. Bernstein16, Eric M. Mendenhall17,18, Daniel R. Zerbino19, Adam Frankish19,  
Paul Flicek19 & Richard M. Myers18
The Encylopedia of DNA Elements (ENCODE) Project launched in 2003 with the 
long-term goal of developing a comprehensive map of functional elements in the 
human genome. These included genes, biochemical regions associated with gene 
regulation (for example, transcription factor binding sites, open chromatin, and 
histone marks) and transcript isoforms. The marks serve as sites for candidate 
cis-regulatory elements (cCREs) that may serve functional roles in regulating gene 
expression1. The project has been extended to model organisms, particularly the 
mouse. In the third phase of ENCODE, nearly a million and more than 300,000 cCRE 
annotations have been generated for human and mouse, respectively, and these have 
provided a valuable resource for the scientific community.
The ENCODE Project was launched in 2003, as the first nearly complete 
human genome sequence was reported2. At that time, our understand-
ing of the human genome was limited. For example, although 5% of the 
genome was known to be under purifying selection in placental mam-
mals3,4, our knowledge of specific elements, particularly with regards 
to non-protein coding genes and regulatory regions, was restricted to 
a few well-studied loci2,5.
ENCODE commenced as an ambitious effort to comprehensively 
annotate the elements in the human genome, such as genes, control 
elements, and transcript isoforms, and was later expanded to annotate 
the genomes of several model organisms. Mapping assays identified 
biochemical activities and thus candidate regulatory elements.
Analyses of the human genome in ENCODE proceeded in succes-
sive phases (Extended Data Fig. 1). Phase I (2003–2007) interrogated 
a specified 1% of the human genome in order to evaluate emerging 
technologies6. Half of this 1% was in regions of high interest, and the 
other half was chosen to sample the range of genomic features (such 
as G+C content and genes). Microarray-based assays were used to map 
transcribed regions, open chromatin, and regions associated with 
transcription factors and histone modification in a wide variety of 
cell lines, and these assays began to reveal the basic organizational 
features of the human genome and transcriptome. Phase II (2007–2012) 
introduced sequencing-based technologies (for example, chromatin 
immunoprecipitation with sequencing (ChIP–seq) and RNA sequencing 
(RNA-seq)) that interrogated the whole human genome and transcrip-
tome7. General assays such as transcript, open-chromatin and histone 
modification mapping were used on a wide variety of cell lines, while 
more specific assays, such as mapping transcription factor binding 
regions, were performed extensively on a smaller number of cell lines 
to provide detailed annotations on, and to investigate the relationships 
of, many regulatory proteins across the genome. Transcriptome analy-
sis of subcellular compartments (the nucleus, cytosol and subnuclear 
compartments) of these cells enabled the locations of transcripts to 
be analysed7.
ENCODE phase III
ENCODE 3 (2012–2017) expanded production and added new types 
of assays8 (Fig. 1, Extended Data Fig. 1), which revealed landscapes of 
RNA binding and the 3D organization of chromatin via methods such as 
chromatin interaction analysis by paired-end tagging (ChIA-PET) and 
Hi-C chromosome conformation capture. Phases 2 and 3 delivered 9,239 
experiments (7,495 in human and 1,744 in mouse) in more than 500 
cell types and tissues, including mapping of transcribed regions and 
transcript isoforms, regions of transcripts recognized by RNA-binding 
proteins, transcription factor binding regions, and regions that harbour 
specific histone modifications, open chromatin, and 3D chromatin 
interactions. The results of all of these experiments are available at 
the ENCODE portal (http://www.encodeproject.org). These efforts, 
combined with those of related projects and many other laborato-
ries, have produced a greatly enhanced view of the human genome 
(Fig. 2), identifying 20,225 protein-coding and 37,595 noncoding genes 
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(Fig. 2a), 2,157,387 open chromatin regions, 750,392 regions with modi-
fied histones (mono-, di- or tri-methylation of histone H3 at lysine 4 
(H3K4me1, H3K4me2 or H3K4me3), or acetylation of histone 3 at lysine 
27 (H3K27ac)), 1,224,154 regions bound by transcription factors and 
chromatin-associated proteins (Fig. 2c), 845,000 RNA subregions occu-
pied by RNA-binding proteins, and more than 130,000 long-range 
interactions between chromatin loci. These annotations have greatly 
enhanced our view of the human genome from its original annotation in 
2003 to a much richer and higher-resolution view (for example, Fig. 2d, e). 
Indeed, although the number of human protein-coding genes known 
has changed only modestly, the number of transcript isoforms, long 
noncoding RNAs (lncRNAs), and potential regulatory regions identified 
has increased greatly since the project began (Fig. 2a–c). An important 
part of ENCODE 3 is that the regulatory mapping efforts have now been 
integrated and synthesized into the first version of an encyclopedia, 
highlighting a registry of 0.9 million cCREs in human and 0.3 million 
cCREs in mouse. Details can be found in the accompanying ENCODE 
paper8 and companion papers in this issue and other journals9–14.
Technology, quality control and standards
Reaching the present annotation required a substantial expansion of 
technology development, from ENCODE groups and others, as well as 
the establishment of standards to ensure that the data are reproduc-
ible and of high quality. Most ENCODE 2 assays used sequence-based 
readouts (for example, RNA-seq15,16 and ChIP–seq17,18) rather than the 
array-based methods19,20 used in the pilot phase, and in ENCODE 3, 
methods such as global mapping of 3D interactions13 and RNA-binding 
regions14 were added. Throughout the project, computational and 
visualization approaches were developed for mapping reads and inte-
grating different data types (Supplementary Note 1).
A key feature of ENCODE is the application of data standards, includ-
ing the use of independent replicates (separate experiments on two 
or more biological samples5,21), except when precluded by the limited 
availability of materials (for example, postmortem human tissues). Of 
the 8,699 ENCODE 2 and ENCODE 3 experiments, 6,101 have independ-
ent replicates. Of equal importance was the use of well-characterized 
reagents, such as antibodies for mapping sites of transcription factor 
binding, chromatin modifications and protein–RNA interactions22. 
ENCODE developed protocols to test each antibody ‘lot’ to demon-
strate their experimental suitability, captured extensive metadata, and 
implemented controlled vocabularies and ontologies. Standards for 
reagents, experimental data, and metadata are on the ENCODE website: 
https://www.encodeproject.org/data-standards/.
Many metrics, including sequencing depth, mapping characteristics, 
replicate concordance, library complexity, and signal-to-noise ratio, 
were used to monitor the quality of each data set, and quality thresholds 
were applied21. A minority of experiments that fell short of the standards 
(for example, insufficiently validated antibodies) are still reported, but 
are marked with a badge to indicate that an issue was found. This is a 
compromise for having some data versus none when an experiment 
did not meet ENCODE-defined thresholds.
An important component is uniform data processing. Data from the 
major ENCODE assays (ChIP–seq, DNase I hypersensitive sites sequenc-
ing (DNase-seq), RNA-seq, and whole-genome bisulfite sequenc-
ing (WGBS)) are uniformly processed and the processing pipelines 
are available for users to apply to their own data, by downloading the 
code from the GitHub (http://github.com/ENCODE-DCC) or by access-
ing the pipelines at the DNAnexus cloud provider. The standards and 
pipelines will continue to evolve as new technologies arise and are 
implemented.
The ENCODE Consortium is a good example of how large-scale group 
efforts can have a large impact on the scientific community, and many 
other national and international projects—including the NIH Road-
map Epigenomics Program, The Cancer Genome Atlas (TCGA), the 
International Human Epigenome Consortium (IHEC), BLUEPRINT, the 
Canadian Epigenetics, Environment and Health Research Consortium 
(CEEHRC), the Genotype and Tissue Expression Project (GTEx), Psy-
chENCODE, Functional Annotation of Animal Genomes (FAANG), the 
Global Alliance for Genomics and Health (GA4GH), the 4D Nucleome 
Program (4DN), the Human Cell Atlas and the FANTOM consortium—
have now formed (Supplementary Note 1). ENCODE has engaged with 
most of these consortia to share standards for data quality control, 
submission, and uniform processing and has helped to facilitate the 
use of common ontologies with some of these consortia. Data from 
the now-completed NIH Roadmap Epigenomics Program have been 
reprocessed and are available in the ENCODE database and are part of 
the Encyclopedia annotation. ENCODE continues to work with other 
consortia, individually and as part of the IHEC and GA4GH (for example, 
http://epishare-project.org) to increase data interoperability and the 
value of its resources.
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Fig. 1 | ENCODE assays by year. Accumulations of assays over the three phases 
of ENCODE. 3D chromatin structure includes ChIA-PET (62 experiments), Hi-C 
(31), and chromatin conformation capture carbon copy (5C, 13). Chromatin 
accessibility includes DNAase-seq (524), assay for transposase-accessible 
chromatin using sequencing (ATAC-seq, 129), transcription activator-like 
effector nuclease (TALEN)-modified DNAase-seq (40), formaldehyde-assisted  
isolation of regulator elements with sequencing (FAIRE-seq, 37) and 
micrococcal nuclease digestion with deep sequencing (MNase-seq, 2). DNA 
methylation includes DNAme arrays (259), WGBS (124), reduced-representation 
bisulfite sequencing (RRBS, 103), methylation-sensitive restriction enzyme 
sequencing (MRE-seq, 24) and methylated DNA immunoprecipitation coupled 
with next-generation sequencing (MeDIP-seq, 4). Histone modification includes 
ChIP–seq (1,605) on histone and modified histone targets. Knockdown 
transcription includes RNA-seq preceded by small interfering RNA (siRNA, 54), 
short hairpin RNA (shRNA, 531), clustered regularly interspaced short 
palindromic repeats (CRISPR, 50) or CRISPR interference (CRISPRi, 77). RNA 
binding includes enhanced cross-linking immunoprecipitation (eCLIP, 349), 
RNA bind-n-seq (158), RNA immunoprecipitation sequencing (RIP-seq, 158), 
RNA-binding protein immunoprecipitation-microarray profiling (RIP-chip, 32), 
individual nucleotide-resolution CLIP (iCLIP, 6) and Switchgear (2). 
Transcription includes RNA annotation and mapping of promoters for the 
analysis of gene expression (RAMPAGE, 155), cap analysis gene expression 
(CAGE, 78), RNA paired-end tag (RNA-PET, 31), microRNA-seq (114), microRNA 
counts (114), more classical RNA-seq (900) and RNA-microarray (170), including 
112 experiments at single-cell resolution. Transcription factor (TF) binding is 
ChIP–seq on non-histone targets (2,443). Other assays include genotyping array 
(123), nascent DNA replication strand sequencing (Repli-seq, 104), replication 
strand arrays (Repli-chip, 63), tandem mass spectrometry (MS/MS, 14), 
genotyping by high-throughput sequencing (genotyping HTS, 12) and DNA-PET 
(6) can be looked at in detail at https://www.encodeproject.org.
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ENCODE as a resource
The purpose of ENCODE is to provide valuable, accessible resources 
to the community. ENCODE data and derived features are available 
from a publicly accessible data portal (https://www.encodeproject.
org), and consent was obtained from donors to make data freely avail-
able to the public. Raw and processed data are available directly from 
the cloud as an Amazon Public Data Set (https://registry.opendata.
aws/encode-project/). The data are widely used by the scientific com-
munity—more than 2,000 publications from researchers outside 
of ENCODE have used ENCODE data to study diverse topics (Fig. 3). 
Because most disease-associated common variants are noncoding 
and show substantial enrichment in candidate cell-type-specific cis 
regulatory elements23,24, ENCODE-derived resources, both in isolation 
and in conjunction with data from other resources (for example, GTEx), 
can help to identify and interpret disease-associated noncoding vari-
ants (Fig. 3a). Users engage with the data in many ways, ranging from 
downloads of multiple data sets to detailed investigations of specific 
loci. Anyone navigating a major genome browser has access to thou-
sands of biochemical, functional, and computational annotations to 
display at any genomic scale or to overlay on any sequence variant. 
Maps of epigenomic features relevant to gene regulation have been 
integrated to form a registry of discrete elements that are candidates 
for enhancers, promoters, or other regulatory elements. A specialized 
browser, SCREEN (http://screen.encodeproject.org), is an interface that 
can be used to identify and study these cCREs and associated ENCODE 
data and other annotations. This dynamic registry will be regularly 
updated as additional information is acquired.
Mouse ENCODE and modENCODE
Model organism studies have produced essential insights into almost 
every aspect of biology, including genome organization and function. 
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Fig. 2 | Progress in annotating the human genome. Link to high-resolution 
PDF file: https://www.dropbox.com/s/rjdrcqygz15p034/perspective.
pdf?dl=0. a, Improvement of gene annotations in the past 15 years by 
GENCODE, an international gene annotation group that uses ENCODE data42.  
b, ENCODE annotations in 2012 with phase II data. Bars show the percentages of 
the mappable human genome (3.1 billion nucleotides; hg19) that were 
annotated as open chromatin by DNase-seq data, enriched in four types of 
active histone mark according to ChIP–seq data, and annotated as 
transcription factor binding sites (TFBSs) according to ChIP–seq data. Also 
shown are percentages of the genome assigned as transcription start sites 
(TSSs), enhancers and the insulator-binding protein (CTCF) by combining 
ChromHMM and Segway genome segmentations7. c, ENCODE annotations in 
2019 with ENCODE 2, Roadmap, and ENCODE 3 data. The registry of cCREs 
developed during phase III defines 0.3%, 1.1%, 5.8%, 0.2% and 0.4% of the human 
genome as cCREs with promoter-like signatures (PLS), proximal enhancer-like 
signatures (pELS), distal enhancer-like signatures (dELS), with high DNase, high 
H3K4me3 and low H3K27ac signals (DNase-H3K4me3), and bound by CTCF, 
respectively. d, A UCSC genome browser view of GENCODE genes (V7) 
coloured by transcript annotation (blue for coding, green for noncoding, and 
red for problematic) and combined genome segmentation (TSSs in red, 
enhancers in orange, weak enhancers in yellow, transcription in green, 
repressed in grey) at the CTCF locus on the hg19 human genome. e, The UCSC 
genome browser view of GENCODE genes (V28, coloured as in d) and cCREs at 
the CTCF locus on the hg38 human genome8. Promoter-like, enhancer-like, and 
CTCF-only cCREs annotated in B cells are in red, yellow, and blue, respectively. 
The last four tracks show the DNase, H3K4me3, H3K27ac, and CTCF signals in B 
cells.
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During ENCODE 2, mapping of mouse epigenomic and transcriptomic 
features was conducted in adult mouse tissues and cell lines through 
the Mouse ENCODE Project25, which identified 21,978 protein-coding 
regions, 32,168 noncoding genes, 1,192,301 open chromatin regions, 
722,334 regions with modified histones H3K4me1, H3K4me2, H3K4me3, 
or H3K27ac, and 686,294 regions bound by transcription factors.
During ENCODE 2, a model organism ENCODE project (modEN-
CODE26,27) was conducted to characterize the transcriptome, epige-
nome, and transcription factor binding sites in Drosophila melanogaster 
and Caenorhabditis elegans tissues, developmental stages and cell lines 
(Extended Data Fig. 1). These organisms provided the opportunity to 
develop detailed records of epigenomic features and transcriptome 
maps throughout development, which is difficult to accomplish in 
humans. Deep mapping of the spatial and temporal transcriptomes 
of these species has substantially enhanced the annotation of both 
genomes. Similarly, detailed mapping of the regulatory circuits that 
govern gene regulation in Drosophila and C. elegans has provided 
insights into general principles of genome organization and func-
tion. Mapping of transcription factor binding sites in Drosophila and 
C. elegans has continued after modENCODE ended in a project called 
model organism Encyclopedia of Regulatory Networks (modERN) 
and to date has characterized more than 262 transcription factors in 
Drosophila and 217 transcription factors in C. elegans28. Collectively, 
the modENCODE Project has provided new insights about how the 
genomes of multicellular organisms direct development and maintain 
homeostasis.
In ENCODE phase III, experiments were carried out to characterize 
dynamic histone marks and accessibility, DNA methylomes, and tran-
scriptomes in samples taken during eight mouse fetal developmental 
stages with up to twelve tissues per stage28–30 (Fig. 4). The resulting more 
than 1,500 datasets comprise, to our knowledge, the most compre-
hensive study of epigenomes and transcriptomes during the prenatal 
development of a mammal. Integrative analysis of these datasets has 
expanded our knowledge of the transcriptional regulatory networks 
that regulate mammalian development and underscored the role of 
gene regulatory mechanisms in human disease. At least 214,264 of the 
candidate enhancers identified in fetal mouse tissues are conserved 
in the human genome8. The human orthologues of these potential 
regulatory elements are significantly enriched for genetic variants 
that are associated with common illnesses in a tissue-restricted man-
ner, providing information for investigations of the molecular basis 
of human disease29,30.
The mouse data from ENCODE 3 also include the results of more than 
400 experiments using transgenic reporter mice designed to assess 
the function of cCREs in three embryonic tissues at two developmen-
tal stages. The results of this systematic study have helped to predict 
the in vivo activities of cCREs. For example, stronger enrichment for 
epigenetic signatures of enhancer activity correlated with higher rates 
of validation in the corresponding tissue29,31.
Finally, comparisons of epigenome and transcriptome maps across 
species have led to insights into the evolution of transcribed regions 
and regulatory information25,32. Combinatorial histone modification 
patterns at cis-regulatory elements and other genomic features are 
broadly conserved in metazoans. These chromatin states and tran-
script levels are highly correlated across tissues and developmental 
stages in all species examined. However, a notable fraction of specific 
cis-regulatory elements undergoes sequence and functional turnover 
during evolution, indicating that some regulatory components show 
substantial plasticity in their evolution while operating in a conserved 
regulatory network33.
Current limitations: phase IV and beyond
It is now apparent that elements that govern transcription, chromatin 
organization, splicing, and other key aspects of genome control and 
function are densely encoded in the human genome; however, despite 
the discovery of many new elements, the annotation of elements that 
are highly selective for particular cell types or states is lagging behind. 
For example, very few examples of condition-specific activation or 
repression of transcriptional control elements are currently annotated 
in ENCODE. Similarly, information from human fetal tissue, reproduc-
tive organs and primary cell types is limited. In addition, although 
many open chromatin regions have been mapped, the transcription 
factors that bind to these sequences are largely unknown, and little 
attention has been devoted to the analysis of repetitive sequences. 
Finally, although transcript heterogeneity and isoforms have been 
described in many cell types, full-length transcripts that represent the 
isoform structure of spliced exons and edits have been described for 
only a small number of cell types.
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a, Publications over time. Community publications appear to use ENCODE data 
and do not report ENCODE grant support in PubMed; consortium publications 
report ENCODE grant support in PubMed. In brief, community publications are 
identified using two steps; first, candidates are identified through automated 
searches for citation of ENCODE accession numbers, ENCODE flagship papers, 
or resources such as HaploReg and RegulomeDB; second, candidates are 
manually evaluated to determine whether ENCODE data were actually used. 
Consortium papers are identified through automated searches of PubMed for 
publications that were supported at least in part by ENCODE awards, and are 
not further evaluated or annotated. b, Human disease example publications. 
The subset of community publications that were annotated as ‘human disease’ 
(other categories are basic biology, software tool, fly/worm data) were further 
manually categorized by disease aetiology.
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Thus, as part of ENCODE 4, considerable effort is being devoted 
to expanding the cell types and tissues analysed (see URLs in Sup-
plementary Note 1) as well as mapping the binding regions for many 
more transcription factors and RNA-binding proteins. These efforts 
are largely focused in a few reference cell lines, with the hope that 
improved knowledge will help with imputation or predictions in other 
cell states34. Single-cell transcriptome capture agents35 and open 
chromatin assays36 are also being applied to increase our understand-
ing of the cellular heterogeneity of different tissues and samples. 
These efforts will supplement the many related activities that are also 
being pursued by HCA, HuBMAP and others37,38. Extensive mapping 
efforts of all types will continue in both the human and mouse, and 
parallel efforts to map transcription factor binding sites are being 
pursued in the Drosophlia and C. elegans by the modERN Project28. 
Full-length transcript isoforms are being elucidated in different 
cell types using long-read sequencing technologies39. ENCODE will 
continue to work with other consortia, and the data from different 
groups and individual laboratories will need to be consolidated into 
a common repository.
Importantly, although very large numbers of noncoding elements 
have been defined, the functional annotation of ENCODE-identified 
elements is still in its infancy. High-throughput reporter-based assays40, 
CRISPR-based genome and epigenome editing methods41, and other 
high-throughput approaches are being used in the current phase of 
ENCODE to assess the functions of many thousands of elements and to 
relate those functional results to their biochemical signatures. These 
targeted functional assays, combined with the large-scale annotation 
of biochemical features, should further enhance the value of ENCODE 
data.
Through these and other efforts, it is expected that many more 
elements in the human genome will be identified across a variety of 
cell types and conditions, their activities will be revealed (often at 
the single-cell level), and their biological functions will be inferred 
more accurately. The development of a systems-wide understanding 
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of function and integration with genetic information associated with 
human traits will greatly enhance our understanding of human biol-
ogy and disease.
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Extended Data Fig. 1 | ENCODE timeline. Pilot phase: September 2003–September 2007; ENCODE 2: September 2007–September 2012; ENCODE 3: September 
2012–January 2017; ENCODE 4: February 2017–present; modENCODE: April 2007–April 2012; mouse ENCODE: 2009–2012.
